Ningxia Zhongke Biotechnology Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Rui Chen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	2yrs

Jüngste Management Updates

Recent updates

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump

Jul 12

Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)

Jun 03

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless

Apr 21

Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues

Feb 27

Geschäftsführer

Rui Chen (49 yo)

no data

Amtszeit

CN¥970,000

Vergütung

Mr. Rui Chen serves as General Manager of Ningxia Zhongke Biotechnology Co., Ltd. and served as its Director until July 01, 2022. Mr. Chen served as Chief Financial Officer of Ningxia Zhongke Biotechnology...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Baoqing Shentu	Independent Director	2yrs	keine Daten	keine Daten
Xiufeng Yue	Independent Director	2yrs	keine Daten	keine Daten
Can Ting Zhu	Director	2yrs	keine Daten	keine Daten
Cun Zai Han	Chairman of the Supervisory Board	no data	keine Daten	keine Daten
Xu Ran	Supervisor	no data	keine Daten	keine Daten
Chao Lin	Director	2yrs	keine Daten	keine Daten
Yijie Lou	Independent Director	2yrs	keine Daten	keine Daten
Jiangming Wu	Chairman	2.6yrs	keine Daten	keine Daten
Bin Li	Director	2yrs	CN¥47.30k	keine Daten
Yankun Li	Director	2yrs	CN¥50.80k	keine Daten
Chun hai Hu	Director	2yrs	keine Daten	keine Daten
Xinling Wang	Independent Director	2yrs	keine Daten	keine Daten

2.0yrs

Durchschnittliche Betriebszugehörigkeit

49yo

Durchschnittliches Alter

Erfahrener Vorstand: 600165Die Vorstandsmitglieder gelten nicht als erfahren ( 1.8 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Ningxia Zhongke Biotechnology Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Insufficient new directors

Less than half of directors are independent

Recent updates

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump

Now 27% overvalued

Ningxia Zhongke Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 15, 2024

Now 24% overvalued

Now 21% overvalued

Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)

Now 23% overvalued

Ningxia Zhongke Biotechnology Co., Ltd(SHSE:600165) dropped from Shanghai Stock Exchange Composite Index

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.68 loss per share (vs CN¥0.21 loss in FY 2022)

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless

Ningxia Zhongke Biotechnology Co., Ltd to Report Q1, 2024 Results on Apr 30, 2024

Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues

Ningxia Zhongke Biotechnology Co., Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released

Ningxia Zhongke Biotechnology Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.046 profit in 2Q 2022)

Ningxia Zhongke Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.034 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released

Ningxia Xinri Hengli Steel Wire Rope Co., Ltd (SHSE:600165) entered into an agreement to acquire 10% stake in Ningxia Hengli Biological New Material Co., Ltd. from Shizuishan Zhengxingcheng New Material Technology Partnership Enterprise (Limited Partnership) for CNY 106 million.

Full year 2021 earnings released: CN¥0.034 loss per share (vs CN¥0.031 profit in FY 2020)

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.005 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.02 loss per share (vs CN¥0.012 loss in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.031 (vs CN¥0.066 loss in FY 2019)

New 90-day low: CN¥5.82

New 90-day low: CN¥6.71

New 90-day high: CN¥8.42

Third quarter earnings released

Shizuishan Zhengxingcheng New Material Technology Partnership Enterprise (Limited Partnership) agreed to acquire 10% stake in Ningxia Hengli Biological New Material Co., Ltd. from Ningxia Xinri Hengli Steel Wire Rope Co.,Ltd (SHSE:600165).

First half earnings released

First half earnings released

New 90-day high - CN¥8.15

Ningxia Xinri Hengli Steel Wire Rope Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter